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management of acute severe colitis: A 
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Abstract 
Introduction 
Lack of comparative trial data on dosing regimens of infliximab in acute severe ulcerative 
colitis (ASUC) patients failing intravenous (IV) corticosteroids has resulted in variability of 
rescue regimes in ASUC with potential impact on clinical outcomes. We aimed to evaluate 
practice variability and physician perspectives in decision making with rescue therapy. 
Methodology 
An internet-based survey of members of the IBD section of British Society of 
Gastroenterology (BSG) was conducted. The survey evaluated provider characteristics and 
general practice in the setting of ASUC, followed by a vignette with linked questions.  
Results 
The response rate of the survey was 31% (209/682 IBD section members). 134 (78%) 
reported they would use standard infliximab dose (5 mg/kg) while 37 (22%) favoured a 
higher front-loading dose of 10 mg/kg citing low albumin, high CRP as their reason for their 
preference. IBD specialists chose the higher front-loading dose more often compared to other 
gastroenterologists (p=0.01) 
In the specific case vignette, accelerated induction (AI) was favoured by 51% of the 
respondents while 25% used the standard induction regime and 19% favoured colectomy. 
IBD specialists more often favoured AI compared to other gastroenterologists(p=0.03) with 
main reason being presence of predictors of low infliximab levels (74%). The reasons cited 
for favouring standard induction (n=57) included lack of evidence for AI (18), their usual 
practice (11), unlicensed regime (7), and safety concerns (4).  
Conclusions 
There are significant variations in practice in the use of infliximab rescue therapies with an 
urgent need for development of care pathways to standardise practice 
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Summary Box 
What is already known about this subject? 
There is variation in rescue therapy regimens used in steroid refractory acute severe 
ulcerative colitis (ASUC) 
What are the new findings? 
This is the first UK survey evaluating clinicians decision making in the choice of rescue therapy in the 
management of ASUC 
How might it impact on clinical practice in the foreseeable future? 
Practice protocols with more available data will help in reducing variability and standardising care 
 
 
 
 
  
Introduction 
In population-based studies, patients with ulcerative colitis (UC) have a 15 to 25% life time 
risk of requiring hospitalization due to acute severe colitis (ASUC) (1,2). More than a third of 
patients with ASUC fail to respond to first line treatment with intravenous (IV) 
corticosteroids (3). In these patients rescue therapy using infliximab or ciclosporin has been 
evaluated as second line medical therapy as an alternative to colectomy (4). Although no 
difference in relative efficacy between these two agents has been noted in randomised 
controlled trials (5,6), infliximab is more often used in clinical practice settings owing to 
safety concerns and challenges with the administration of ciclosporin (7). However, even in 
the era of rescue therapy for ASUC, one in 5 patients still requires a colectomy within three 
months of admission (8, 9) indicating the need for further optimisation of therapies.  
The dosing schedules used in ASUC were adopted from the original infliximab licencing 
trials which were in a moderate-severe ambulatory UC cohort. Currently there are no 
published randomised clinical trials which guide the optimal initial dosing in the setting of 
ASUC. Disease-related and pharmacokinetic factors may have a role in the response rates to 
rescue therapy with infliximab (10,11,12,13) with these patients needing more drug at the 
outset. This has led to the concept of accelerated induction in ASUC using either a higher 
`front-loading dose` of 10 mg/kg instead of standard 5mg/kg dosing or using more frequent 
dosing with 5 mg/g  given earlier than 2 weeks after the first dose (chaser regime)  (14). 
However, the data on the effectiveness and safety of these strategies are conflicting and are 
limited to small retrospective observational studies (15,16,17,18). Indeed, a recent meta-
analysis did not report any significant difference in short term or long-term colectomy rates 
with accelerated induction (19). One of the biggest drawbacks of these studies is the potential 
for provider bias due to variations in practice by the treating clinician both in relation to 
regime, dose and timing of initial and subsequent dosing of infliximab.  
In the absence of robust comparative trial data, the variability in this setting highlights the 
urgent need for a learning network and potential development of care pathways which can be 
audited for outcomes. This is the focus of ELEVATE ASUC Study programme 
(ClinicalTrials.gov Identifier: NCT03907631), initiated in the United Kingdom. The aims of 
the survey, detailed here and included in the ELEVATE ASUC programme, were to evaluate 
the perspectives, decision making and practices of gastroenterologists managing ASUC and 
to identify variability in practice among UK gastroenterologists. 
Materials and Methods 
We created an internet-based survey using Google Docs (Google Inc, Mountain View, CA, 
USA) in two sections. The first section of the questionnaire evaluated provider characteristics 
such as place of work (university teaching hospital versus general hospital), subspecialist 
expertise in relation to inflammatory bowel disease (IBD), years of experience and the 
average number of patients with ASUC seen per year. We enquired regarding variations in 
the management of ASUC such as joint care with colorectal surgery, MDT discussion and 
timing of endoscopic evaluation. We also captured clinical perspectives in relation to the use 
of rescue therapy, including the choice of therapy and dosing schedule. The second section of 
the questionnaire was based on a clinical vignette of a patient with ASUC failing IV 
corticosteroid therapy. A linked-question format allowed the respondents to be directed to the 
subsequent question and clinical scenario based on their answer to the preceding question. In 
the initial questions about the case vignette, respondents were asked about their diagnostic 
and therapeutic approaches to a patient hospitalised with ASUC. In the subsequent part of the 
vignette, the decision-making process following failure of IVCS after 3 days of admission, 
the response to initiation and assessment of rescue therapy were evaluated. Finally, we also 
used the survey to understand the perspectives of the clinicians on the unmet needs and data 
gaps which needs to be addressed by future studies on ASUC. 
The survey was circulated to all members of the IBD section of the British Society of 
Gastroenterology. The survey was anonymous and participation was voluntary.  
Data were collected on Google Docs and exported for analysis to Microsoft Excel (Microsoft 
Corp, Redmond, WA, USA). We performed analysis using Microsoft Excel and SPSS 
version 25 (IBM Corp, Armonk, NY, USA). Response frequencies were tabulated and 
expressed as percentages of total responses. For quantitative variables, mean and standard 
deviation were calculated if they had a normal distribution or median and interquartile range 
otherwise. The responses were compared using Fisher’s exact test for  categorical variables. 
A p-value of <0.05 was taken as significant.  
 
Results  
A total of 209 responses were received for the survey distributed to 682 IBD section 
members of the BSG representing a response rate of 31%. The demographics of the 
respondents are presented in Table 1. Majority of the respondents (91%) declared themselves 
as IBD specialists or gastroenterologists with specialist interest in IBD. Nearly half of the 
respondents saw less than 10 patients per year with ASUC.  
 
Table 1: Provider characteristics 
Clinicians role  
(n, %) 
IBD specialist 40 (20%) 
Gastroenterologist with special interest in IBD 144 (71%) 
Gastroenterologist with special interest outside 
IBD 
21(10%) 
Type of 
clinician`s 
institution (n, %) 
University Teaching Hospital 82 (40%) 
 General Hospitals  126 (60 %) 
Years of 
experience at 
consultant level 
(n, %) 
< 5 years 60 (29%) 
5-9 years 70 (34%) 
10-19 years 55 (26%) 
>20 years 23 (11%) 
Average number 
of ASUC 
admissions per 
year under the 
care of 
respondent  
<5 patients 15 (7%) 
5-9 patients 83(40%) 
10-19 patients 80 (38%) 
>20 patients 30 (14%) 
 
 
 
Process characteristics- Non vignette based  
The processes involved in management of hospitalised ASUC patients in the institutions of 
the respondents are indicated in Table 2.  
Table 2: Process characteristics in ASUC management 
Primary team for 
inpatient 
management of 
ASUC 
Gastroenterologist 180 (87%) 
Colorectal surgeon  0 (0%) 
Joint care with gastroenterologist and 
colorectal surgeon 
  26 (12%) 
Proportion of ASUC 
patients discussed at 
IBD MDT 
 (n, %) 
<25% 109 (52%) 
25-49% 22 (11%) 
50-74% 33 (16%) 
75-100%  44 (21%) 
Timing of surgical 
opinion in ASUC 
patients (n, %) 
All patients within 24 hours of admission  160 (11%) 
All patients within 48 hours of admission 43 (21%) 
At failure of first line therapy 106 (51%) 
At the failure of rescue therapy/when 
surgery is indicated  
37 (18%) 
Routinely do 
imaging in ASUC 
patients (n, %) 
Always abdominal X-ray at admission 160 (77%) 
Abdominal CT at admission 2 (1%) 
Abdominal CT only if suspecting 
complications 
13 (6%) 
Not routinely image, only in selected 
patients  
33 (16%) 
Routinely do 
sigmoidoscopy in 
ASUC patients (n, 
%) 
Yes as soon as possible but within 48 hours 
of admission 
88 (43%) 
Yes as soon as possible but may be >48 
hours after admission 
91 (44%) 
Not routinely, only if no response to steroids   27 (13%) 
Routinely check for 
CMV in ASUC 
patients (n, %) 
Yes, both in biopsies and serology 53 (26%) 
Yes, only in biopsies 100 (49%) 
Rarely check 50 (25%) 
Never check  1 (0.5%) 
Offer colectomy as 
alternative option to 
intravenous steroids 
No 176 (85 %) 
Yes 32 (15%) 
Offer rescue therapy 
in steroid non-
responsive  
Yes 204 (99 %) 
No 2 (1%) 
Drug used in rescue 
therapy 
Infliximab  123 (60 %) 
Ciclosporin 2 (1%) 
Either infliximab or ciclosporin 81 (39%) 
Local colorectal 
team offer 
laparoscopic 
colectomy in the 
setting of ASUC  
Yes, often 81 (38 %) 
No  86 (41%) 
Occasionally  25 (12%) 
Unsure  16 (8%) 
Number of days of 
IV steroids before 
considering rescue 
therapy 
2 days 4 (2%) 
3 days  165 (79%) 
5 days 28 (13%) 
7 days 11 (5%) 
The majority of the hospitalised ASUC patients (88%) were admitted and managed primarily 
under gastroenterologists with only 12% respondents indicating joint care with colorectal 
surgeons and none indicating colorectal surgery as the primary team for initial management. 
Only 20% of respondents indicated they routinely held a multidisciplinary team meeting 
discussion for patients with ASUC, and over half of the respondents reported MDT 
discussion in less than a quarter of their admissions with ASUC. Nevertheless, 31% of 
respondents sought a colorectal surgical opinion for their patients within 48 hours of 
admission with ASUC while 51% and sought a colorectal surgical opinion after failure of 
first line therapy with intravenous steroids and 18% sought one at the point when no further 
medical therapy is feasible. Three quarters of the respondents routinely performed an 
abdominal x-ray at admission while 7% performed an abdominal CT scan. 87% organised a 
flexible sigmoidoscopy during the admission of an ASUC patient with over half of these 
performed within 24 hours after admission while the remaining 13% only performed 
sigmoidoscopy if there was lack of response to initial medical therapy. Presence of 
cytomegalovirus (CMV) was routinely checked in biopsies in 49% of respondents and by 
biopsies plus serology and 26% of the respondents. 
Medical therapy was the initial approach to an admitted patient with ASUC for 85% of 
respondents with almost 90 % favouring intravenous hydrocortisone while 15% felt that 
colectomy should be offered as an alternative to medical therapy at admission. Three days of 
intravenous steroids was the timepoint for assessing response was favoured by 79% of the 
respondents while 13% and 5% preferred to wait 5 and 7 days respectively to assess response. 
Ninety nine percent of respondents will consider offering rescue therapy following failure of 
intravenous steroids while two respondents favoured colectomy in the setting of steroid 
failure. The factors taken into account by the respondents before consideration of rescue 
therapy are depicted in Figure 1.  
 
Majority (60%) will only consider infliximab for rescue therapy while 39% will consider 
either infliximab or ciclosporin as their rescue therapy drug. Laparoscopic colectomy was not 
available from colorectal surgeons as an option in the setting ASUC in the sites of the 41% of 
the respondents. 
Case Vignette based practice characteristics  
Initial management 
Upon admission of a patient with ASUC, 91% of the respondents indicated they would 
promptly initiate intravenous corticosteroids without waiting for the result of the stool 
cultures for enteric pathogens, while 8% of the respondents preferred to wait for the results of 
cultures before initiating IV steroids. Only two respondents (1%) favoured starting infliximab 
along with steroids. Both these respondents reported the reason for choosing  infliximab at 
admission along with steroids to be the  severity of presentation, noting low albumin, very 
high stool frequency and low haemoglobin. None of the respondents favoured colectomy at 
presentation. Routine antibiotic use was not favoured by the majority, while 17% would 
initiate antibiotics along with IV steroids. Flexible sigmoidoscopy with and without bowel 
preparation would be performed by 16.5% and 76% respectively while 8% preferred to delay 
endoscopic evaluation. The majority of respondents (77%) indicated they would assess their 
patient for response to steroids on Day 3 and 7% preferred an earlier evaluation on Day 2 
after admission. 
Management following failure of intravenous steroids Day 3 
A pictorial summary of the therapeutic decision making in case vignette is depicted in Figure 
2:  
 
On failure of response to intravenous steroids by day 3, 83% of respondents elected to start 
infliximab rescue therapy while 10% elected to persevere with steroids. Ciclosporin was 
chosen for rescue therapy by 6% and 3 respondents (1.5%) favoured colectomy to rescue 
therapy. Of the 19 respondents who favoured the continuation of steroids for more than 3 
days before decision, all but one favoured initiation of standard dose (5 mg/kg) of infliximab 
rescue when asked to review their treatment decision in the context of persistent IV steroid 
failure at 5-7 days. Among the respondents initiating on infliximab rescue therapy (171 
respondents), 78% favoured standard dose rescue while a higher front-loading dose of 
10 mg/kg was preferred by 37 (22%) respondents. The higher dose was preferred by IBD 
specialists compared with other clinicians (p= 0.01) and by those working in university 
teaching hospitals (p= 0.04). The main reasons cited for higher dose included very low 
albumin (38%) very high CRP (32%) and severity of symptoms (16%), while higher dose 
was reported as their normal practice by 15% of respondents. 
In the case vignette, the patient went on to have a suboptimal response to the first dose of 
infliximab rescue. In this context, 75/171 respondents favoured a further dose within 5-7 days 
(44%). However only 16% of the respondents giving an initial 10 mg/kg dose gave a further 
dose within 7 days; the rest favoured colectomy as the next step. In contrast, 52% of those 
starting 5 mg/kg dose opted to give a further dose. The reasons for favouring accelerated 
induction (both higher initial dosing or second dose within 7 days) are depicted in Figure 3. 
IBD specialists favoured accelerated induction more often than other gastroenterologists 
(p=0.03). 
 
 
 
Among those preferring standard first dose, 19% favoured colectomy while 25% elected to 
monitor and give a further dose after 2 weeks. The reasons for not giving accelerated 
induction and for favouring colectomy after lack of response to first dose infliximab are 
detailed in Figure 4 and Figure 5. 
 
Forty percent of respondents based the interval between the first and second doses on the 
clinical response of the patient, while 25% preferred to always give the second dose within 5 
days after the first. Following response to accelerated induction, the third dose was given two 
weeks after the second by 85% of the respondents while 12% indicated they would wait for 
drug levels to make this decision. Eighty percent of respondents said they would continue 
infliximab maintenance until loss of response following successful rescue therapy.  
Perspectives of gaps in data 
The main barriers for using accelerated induction regimes in ASUC patients reported by 163 
respondents included the lack of reliable studies (80/163, 49%), safety concerns (63/163, 
39%) and the absence of predictive markers of non-response (44/163, 27%). Recommended 
aspects to be evaluated in future trials on rescue therapy in ASUC include identifying the best 
initial dose of infliximab (89% of respondents), identifying the biomarkers to identify 
response (56% of respondents) , the value of drug level monitoring in clinical practice (40% 
of respondents) and determining the best maintenance strategy in patients receiving rescue 
therapy (56% of respondents). (See Figure 6) 
 
 
 
Discussion 
There is growing evidence from pharmacokinetic and pharmacodynamic studies that 
infliximab clearance is more rapid in ASUC and this may potentially impact outcomes (21). 
Based on the solid theoretical underpinning of this concept, the community of IBD experts 
appear to have moved towards use of accelerated infliximab regimes in ASUC patients 
without waiting for definitive evidence. However, the data from uncontrolled and 
retrospective studies show conflicting results, and our recent meta-analysis (19) also casts 
doubts on the evidence for such practice. Majority of the current recommendations and 
guidelines (22,23) do not support the use of accelerated induction in the algorithm for 
patients with steroid-refractory ASUC although the recent BSG guidelines (24) support its 
use after a colorectal surgical review to determine whether emergency colectomy is required.  
Our survey provides evidence for the significant variations in management practices in the 
real world setting among gastroenterologists caring for hospitalised patients with ASUC, 
particularly in the scenario of rescue therapy. In contrast to the best practice guidelines 
(22,23), the majority of our admitted patients do not have the benefit of joint care with 
colorectal surgery from the first day of admission with ASUC. Only one fifth of these 
severely ill patients are discussed at MDT meetings in a prospective contemporaneous 
manner. When treating steroid-refractory patients, despite the equal efficacy of ciclosporin 
and infliximab in IV-steroid-refractory ASUC, the majority of clinicians prefer the use of 
infliximab over ciclosporin. This is consistent with the results of a nested study in the 
CONSTRUCT Trial (7), where ease of use, perceived better adverse effect profile and less 
intensive monitoring regimes made clinicians favour infliximab. Furthermore, only a very 
small proportion of our respondents (2%) chose colectomy in the setting of IV steroid failure, 
despite the lack of randomised trials comparing colectomy to medical therapy and the high 
failure rates of rescue therapy in the literature (5,6,8). 
The most marked variability in our survey was in the choice of dosing regimens of infliximab 
rescue therapy in the case vignette. The vignette included a number of variables proven to be 
determinants of altered pharmacokinetics and higher clearance of infliximab such as 
extensive disease, elevated CRP and low albumin (10). Yet only one in 5 respondents 
favoured a higher initial dose of infliximab for rescue. There was also variability in 
considering a second dose following suboptimal response. Only half the respondents 
suggested they would give an additional dose within 7 days, the rest favouring the standard 
regime or suggesting colectomy. There are currently no prospective trials which have clearly 
indicated improved efficacy and safety of accelerated dosing regimens in the hospitalised 
patients with ASUC, and this was once of the main reasons indicated by over 50% our 
respondents for their reluctance to choosing accelerated induction regimes. Nevertheless, half 
of our respondents felt confident in using higher dosing schedule in their patients. 
The timing of the assessment to consider rescue therapy and reassessment of response also 
appear to be inconsistent among the responders. The Travis index (25) is the most commonly 
used index for assessing response to intravenous steroids in ASUC and this recommends 
reassessment after 3 days of IV steroids. In our survey 20 % of respondents preferred to give 
a longer interval of up to 5-7 days before considering rescue therapy or colectomy. Similar 
variation was also seen in the time to reassess response to first dose of rescue therapy with a 
quarter reassessing at 5 days, 33% waiting for 7 days and the others variable intervals based 
on clinical response. The lack of clear biomarkers of response and concerns regarding safety 
of additional dosing may have contributed to this practice variability. 
This is, to the best of our knowledge, the largest survey on practice variations in the setting of 
the management of acute severe colitis. In a retrospective review of the Veterans Healthcare 
System in the USA (26) published three years ago, providers differed in their choice of initial 
therapy for ASUC with 83% providing intravenous steroids but 17% used infliximab as first 
line therapy at admission. In comparison, all of our respondents used intravenous steroids as 
initial therapy and only two of our respondents in the clinical vignette started infliximab 
along with IVCS at admission. In our survey, the majority of the providers in this survey 
(65%) reported use of standard induction regimen dosing (5 mg/kg) and only one third 
performed accelerated induction (26). In contrast, in another internet-based survey of the 
members of the International Organisation for Inflammatory Bowel Disease and Crohn`s and 
Colitis Foundation Clinical Research Alliance (27), only 24% of respondents used the 
standard induction regime of 5 mg/kg at 0, 2 and 6 weeks for ASUC. In this survey 
participants were asked for reasons for giving accelerated dosing of infliximab, and the 
reasons cited were severity of clinical symptoms, high C-reactive protein, low serum albumin 
level and endoscopic severity. This survey only included experts in IBD, and the authors did 
not provide descriptive details such as response rates; both of these may introduce bias in the 
responses. Significant practice pattern variability is also reported from a high-volume tertiary 
referral centre survey in Mount Sinai USA (28). This survey, including 30 senior and junior 
gastroenterologists, suggested a higher proportion of infliximab use as first line therapy 
(17%) compared to our survey. The use of antibiotics, imaging and sigmoidoscopy practised 
in this centre was similar to the responses to our survey. In the Mount Sinai study, however, a 
higher proportion of respondents used a front-loading dose of 10 mg/kg (35%) compared to 
our survey where only 22% of respondents used front loading regime. In this study the choice 
of dosing regime was independent of the level of training. A more recent survey conducted 
among the members of the Spanish Crohn's Disease and Ulcerative Colitis Working Group 
(GETECCU) (29), was limited by the low response rate (20%), and like in our survey almost 
exclusively included gastroenterologists alone. The use of higher front-loading dose of 
infliximab for rescue therapy (56%) and earlier use of the second dose (75%) was more 
prevalent among Spanish gastroenterologists compared with our study. 
There are some limitations of our study which we acknowledge. Firstly, our survey was sent 
only to the members of the IBD section of the British Society of Gastroenterology and hence 
did not capture the perspectives of other members of a multidisciplinary IBD team including 
colorectal surgeons and IBD nurses. In addition, we did not include trainees in the survey, 
and in a number of centres trainees may be the first point of contact with an admitted patient 
with ASUC. However, we feel that decisions pertaining to medical therapy in general and 
rescue therapies ought to be and often are made by senior gastroenterologists with IBD 
interest, and in that respect the survey is representative of the clinical practice scenario in the 
United Kingdom. 
The results of our survey highlight the marked variations in management practises for 
hospitalised ASUC patients, particularly in respect to infliximab rescue therapy.  Reduction 
in variations in care is a key goal of the UK IBD standards (30).  Further data from 
prospective studies are required to fully evaluate the efficacy and safety of different dosing 
regimens in ASUC. We urgently need early predictors of response to intravenous steroids, 
which will allow earlier use of rescue therapies in selected patients. Further understanding of 
factors predictive of response to infliximab rescue therapy in ASUC patients is also required. 
In the interim, we would recommend attempts to reduce variability by introducing care 
bundles or learning networks. 
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